StockData
Autolus Therapeutics plc logo

Autolus Therapeutics plc (AUTL) income statement

AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/3022% below fair value
$1.06−0.03 (-2.75%)

Close on Nov 18, 2026Market cap $282.13MP/E –Yield –

Autolus Therapeutics plc income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
15.7%
Operating margin
-210.8%
Net margin
-238.7%
Return on equity, FY2025
-95.0%

Financial strength

Current ratio
4.89
Debt to equity
–
Debt to assets
–
Cash to current liabilities
249.2%

Valuation

P/E ratio
–
Price to sales
2.40
Price to book
3.77
Dividend yield
–

See a number that looks wrong?